CXCR4 and neoplasm: Relative to [18F]FDG, however, CXCR4 PET has already identified a higher number of atherosclerotic lesions in the vessel wall in oncology patients and, thus, may even provide a more reliable read-out of ongoing inflammatory activities under tumor-specific treatment [64].